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E-mail address: cenk.suphioglu@deakin.edu (C. SuDocosahexaenoic acid (DHA) is the major polyunsaturated fatty acid in neuronal cell membranes.
We hypothesize that DHA induces a decrease in neuronal cell death through reduced ZnT3 expres-
sion and zinc uptake. Exposure of M17 cells to DHA-deﬁcient medium increased the levels of active
caspase-3, relative to levels in DHA-replete cells, conﬁrming the adverse effects of DHA deﬁciency in
promoting neuronal cell death. In DHA-treated M17 cells, zinc uptake was 65% less and ZnT3 mRNA
and protein levels were reduced in comparison with DHA-depleted cells. We propose that the
neuroprotective function of DHA is exerted through a reduction in cellular zinc levels that in turn
inhibits apoptosis.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The omega-3 fatty acid, alpha-linolenic acid (ALA), is an essential
nutrient that cannot be synthesized by mammals [1]. The mamma-
lian brain is rich in a metabolite of ALA known as DHA (docosahex-
aenoic acid, 22:6n-3); this fatty acid is the main polyunsaturated
fatty acid (PUFA) in the brain where it makes up approximately 3%
of the dry weight of the brain [2]. DHA has many diverse functions
at the cellular level including effects on membrane ﬂuidity, regula-
tion of enzymes and ion channels and in signal transduction [3]. Evi-
dence from cell culture and animal models suggests that n-3 PUFA
supplementation attenuates b-amyloid deposition, a hallmark of
Alzheimer’s disease [4–9]. Furthermore, mechanistic studies have
demonstrated that DHA promotes neuronal survival via Akt [10],
Bcl-2 [11] and brain derived neurotrophic factor [12] signalling
pathways. Collectively, these studies along with post-mortem
studies demonstrating lower brain DHA in Alzheimer’s patients
[8,13,14]providemechanistic support for the existenceof a relation-
ship between n-3 PUFA intake and Alzheimer’s disease risk.chemical Societies. Published by E
and Environmental Sciences,
ighway, Burwood, VIC 3125,
phioglu).In a previous study of dietary DHA deﬁciency in rats, we found a
novel link between DHA deﬁciency and altered brain zinc homeo-
stasis. Adult animals on a DHA-deﬁcient diet had decreased plasma
zinc levels, altered brain zinc distribution and increased expression
of a member of the zinc transporter family, ZnT3 (SLC30A3) in the
brain [15]. These ﬁndings are consistent with well-established
links between zinc homeostasis and lipid metabolism [16–19]. A
common feature of both DHA and zinc is their capacity to inﬂuence
neuronal cell death. DHA prevents apoptotic death induced by ser-
um deprivation [18,19] while zinc is a known potent toxic cation
mediating neuronal injury [20] and apoptotic cell death [21]. The
molecular basis of the link between DHA and zinc remains un-
known. Therefore, the aim of the current study was to explore
the link between the omega-3 fatty acid DHA and zinc metabolism,
speciﬁcally in relation to cell death through apoptosis.
2. Materials and methods
2.1. Cell culture
The human neuroblastoma cell line M17 was grown at 37 C in
a humidiﬁed atmosphere in the presence of 5.0% carbon dioxide, as
monolayer cultures in 75 cm2 disposable plastic ﬂasks (Nunc,
Roskilde, Denmark), maintained in 10 ml of Opti-MEM medialsevier B.V. All rights reserved.
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
100 
0 2.5 5 10 20 40 
Pe
rc
en
ta
ge
 v
ia
bl
e 
ce
lls
 
DHA (µg/ml) 
Fig. 1. Cell viability plot of the M17 human neuronal cell line. M17 cells cultured in
the absence and presence of different DHA concentrations (lg/ml) were stained
with Trypan blue and the percentage of viable cells was determined.
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bovine serum (FBS) supplementation. At 90% conﬂuence, M17
cells were harvested or passaged using 0.025% trypsin/EDTA.
M17 cells were seeded at a density of 1  106 cells/75 cm2 ﬂask
and grown to conﬂuence then exposed to media supplemented
with DHA (Sigma–Aldrich, MO, USA; 2.5, 5, 10, 20 and 40 lg/ml ﬁ-
nal concentration). The DHA-containing media had been pre-incu-
bated overnight at 37 C to allow the DHA to conjugate with media
proteins and allow delivery into cells. After 2 days of incubation,
cells were harvested, centrifuged at 1000g for 5 min and pellet
resuspended in PBS. Each sample was then divided into 3 aliquots,
centrifuged at 14 000g for 5 min and cell pellets stored at 80 C
until needed for analysis.
2.2. Fatty acid analysis
M17 cells were cultured with and without DHA (as described
above) and subjected to fatty acid analysis. Cellular phospholipids
were isolated by thin layer chromatography and the phospholipid
fatty acids were then converted to fatty acid methyl esters for
determination of the DHA content by gas chromatography (GC) fol-
lowing our established techniques [22].
2.3. 65Zinc inﬂux experiments
Zinc inﬂux experiments were performed as previously de-
scribed [23]. Brieﬂy, M17 cells were seeded (in triplicate) in 6 well
plates (Nunc, Roskilde, Denmark) at 5  105 cells/well and grown
in the absence or presence of DHA (20 lg/ml) for 2 days, as de-
scribed above. Spent media was removed and replaced with fresh
media containing 65Zinc and 5 lM ZnCl2, in the absence or pres-
ence of DHA (20 lg/ml) and incubated at 37 C for 0, 2, 5, 10, 20
or 60 min. After incubation, cells were gently washed and har-
vested as described above. Harvested cells were pelleted at
8000g for 1 min and radioactive signal was measured with a Per-
kin–Elmer 1480 automatic gamma counter. Total DNA of cell pel-
lets were determined with a Hoechst 33258 dye (Sigma–Aldrich)
and measured by VersaFluor ﬂuorometer (Biorad, NSW, Australia).
Herring sperm DNA (Sigma–Aldrich) was used as the DNA stan-
dard. The speciﬁc activity of the zinc was determined and zinc up-
take was expressed as pmol Zn/lg DNA.
2.4. Real-time PCR analysis
Total RNA was isolated from cell pellets using RNeasy Mini-kit
(Qiagen, VIC, Australia) according to manufacturer’s instructions,
along with DNA-free treatment (Ambion, TX, USA) to remove geno-
mic DNA (see Supplementary data 1 and Supplementary Table 1).2.5. Western blot analysis
Lysis buffer (1% sodium dodecyl sulfate, 10 mM Tris–hydrochlo-
ric acid, pH of 6.8, containing one Mini EDTA-free protease inhibi-
tor cocktail tablet (Roche Applied Science, NSW, Australia) per
10 ml) was added to cells in ﬂasks. Cells were disrupted by passing
through a 21-gauge needle 10 times and sonicated (40% power
output, 30% duty cycle) on ice, three times for 15 s with 30 s break
between each sonication, by using a Microsone Ultrasonic cell dis-
rupter (Misonix Incorporated, NY, USA). Samples were then centri-
fuged at 14 000g for 20 min at 4 C and stored in small aliquots at
80 C until needed for analysis.
Quantiﬁcation of protein concentration, gel electrophoresis and
Western blot analysis was carried out as described previously [24]
and in Supplementary data 2.
2.6. ZnT3 antibody
A synthetic peptide was prepared, consisting of the N-terminal
sequence of the hZnT3 gene (VSPRDRGGAGGSLRL) (Mimotopes,
Australia) was used to raise an antibody to the human protein as
described in Supplementary data 3.
2.7. Immunoﬂuorescence experiments
Immunoﬂuorescence was performed as previously described
[25]. See Supplementary data 4.3. Results
3.1. Proliferation and viability of cultured M17 cells was not affected
by DHA concentrations up to 40 lg/ml over 2 days
Total viable cell counts were performed on M17 cells grown in
medium enriched with DHA concentrations from 0 to 40 lg/ml for
2 days (Fig. 1). In M17 cells treated with 40 lg/ml DHA for 2 days,
the total viable cell count was more than 75%, which was similar to
that of the untreated cells (85%), indicating no direct toxic effect
of DHA at 40 lg/ml.
3.2. Cultured M17 cells incorporated DHA
Gas chromatograph analysis indicated that following treatment
with DHA (20 lg/ml), M17 cells incorporated DHA from the cell
culture medium into the cell membrane phospholipids to a level
4 times that of untreated cells (data not shown), conﬁrming the
successful delivery of DHA to the cells. Gas chromatograph analysis
indicated that undetectable DHA was present in normal (DHA-deﬁ-
cient) culture medium.
3.3. DHA reduced protein levels of caspase-3, an end marker of
apoptosis
M17 cells exposed to 20 lg/ml DHA for 2 days showed a
marked reduction in caspase-3 protein levels compared with un-
treated cells (Fig. 2A) and normalisation to the b-actin housekeep-
ing gene (Fig. 2B) indicated a greater than 66% reduction in
caspase-3 protein levels when compared with the untreated cells
(Fig. 2C).
3.4. The cellular uptake mechanisms of DHA and zinc are not linked
To establish if DHA and zinc shared a common cellular uptake
transport process such as a co-transporter, we measured cellular
accumulation of radiolabelled zinc (65Zn) in the presence and
BA
Fig. 3. Radiolabelled zinc inﬂux studies. M17 cells were cultured either without (A)
or with 20 lg/ml DHA for 2 days (B) prior to zinc inﬂux studies using 65Zn.
Accumulation (inﬂux) of Zn (pmol/lg DNA) in the cells was measured at different
time points (min) before and after exposure to 65Zn in the absence (empty bars) and
presence (solid bars) of 20 lg/ml DHA. The data are shown as means (n = 3,
*P < 0.05).
C
B
A
Fig. 2. Western blot analysis of apoptosis in M17 cells. Caspase-3 (A) and the
housekeeping b-actin (B) protein levels (arrows) of M17 cells cultured in the
absence and presence (5, 10 and 20 lg/ml) of DHA were detected with speciﬁc
antibodies. (C) Densitometric analysis of caspase-3 protein levels (normalised with
the b-actin protein levels) are shown in arbitrary units (AU). Molecular mass
protein markers (Mr) are indicated on the left of each gel. This result is
representative of three similar independent experiments. The data are shown as
means (n = 3, *P < 0.05).
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lets were similar in the presence of 20 lg/ml DHA and in the con-
trol culture medium without DHA (Fig. 3A).
3.5. M17 cells that had incorporated DHA showed reduced cellular zinc
inﬂux
M17 cells were grown in culture medium enriched with DHA
for 2 days prior to exposure to 65Zn for a period of 1 h. DHA-treated
cells showed reduced cellular zinc accumulation over a period of
one hour (Fig. 3B). The decrease in zinc uptake was signiﬁcant at
5 min and more pronounced at subsequent time intervals, relative
to untreated cells. By 1 h, DHA-treated M17 cells had accumulated
only 35% of the amount of zinc of untreated cells.
3.6. M17 cells express a range of zinc transporters belonging to the
SLC30 and SLC39 families
Real-time PCR (Q-PCR) was used to measure the mRNA expres-
sion levels of members of the two major families of zinc transport-
ers SLC30 and SLC39, in M17 cells, relative to expression of ZnT3
(Fig. 4). The M17 cells expressed all of the transporters tested.
The most highly expressed zinc transporters were ZnT6 and ZnT7.
3.7. DHA reduced mRNA levels of ZnT3 in M17cells
Since ZnT3 has a potentially signiﬁcant role in the brain as a
putative transporter of zinc into synaptic vesicles, we next investi-gated the effect of DHA on ZnT3 expression levels. Real-time PCR
analysis of M17 cells grown either in DHA-enriched or DHA-deﬁ-
cient culture medium indicated that ZnT3 mRNA expression levels
were reduced by more than 12-fold in the presence of 40 lg/ml
DHA (Fig. 5).
3.8. DHA reduced protein expression levels of ZnT3 in M17 cells
Western blot analysis to assess changes in ZnT3 protein levels
in response to DHA treatment indicated that in cells exposed to
20 lg/ml DHA, ZnT3 protein levels were markedly reduced when
compared with the untreated cells (Fig. 6A), and normalisation to
the b-actin housekeeping gene (Fig. 6B) indicated a greater than
47% reduction in ZnT3 protein levels with 20 lg/ml DHA compared
with the untreated cells (Fig. 6C).
3.9. DHA does not affect ZnT3 localisation in M17 cells
Immunolocalisation studies to assess whether DHA inﬂuenced
the localisation of ZnT3 in M17 neuronal cells showed a similar
granular cytoplasmic localisation both in M17 cells cultured with
(Fig. 7A) and without (Fig. 7B) DHA. This is consistent with the
intracellular vesicular localisation previously described for ZnT3.
4. Discussion
Both DHA and zinc play crucial, but seemingly independent
roles in brain function. Alterations in both DHA levels and zinc
Fig. 4. Real-time PCR analysis of the different zinc transporters in M17 cell line. Fold-difference of mRNA levels of the different putative zinc inﬂux (Zip1–Zip4) and efﬂux
(ZnT1–ZnT7) transporters measured relative to that of ZnT3.
Fig. 5. Real-time PCR analysis of ZnT3 in M17 cells. M17 cells cultured in the absence and in the presence of different DHA concentrations (lg/ml) showing fold-difference of
mRNA levels (solid bars) when compared to the no DHA control. Fold-difference of less than 2 and more than 2 (grey shaded area) can be considered as unreliable
background noise and therefore not signiﬁcant. The data are shown as means (n = 3, *P < 0.05).
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[8,26]. Our previous data revealed a link between DHA deﬁciency
and altered zinc homeostasis in the brain of rats fed on a DHA-deﬁ-
cient diet [15]. Although these data demonstrated a clear relation-
ship between DHA metabolism and zinc homeostasis, the
molecular mechanisms of this interaction have not been eluci-
dated. In the current study, we have shown that DHA reduces cel-lular zinc uptake possibly mediated by the zinc transporter ZnT3,
with subsequent reduced apoptotic cell death. This indicates that
the adverse effects of dietary DHA deﬁciency in promoting neuro-
degenerative brain disorders may be mediated, at least in part,
through altered zinc ﬂuxes.
We tested the hypothesis that the link between zinc and DHA
may be due to a shared plasma membrane transport process such
CB
A
Fig. 6. Western blot analysis of ZnT3 expression in M17 cells. ZnT3 (A) and the
housekeeping b-actin (B) protein levels (arrows) of M17 cells cultured in the
absence and presence (5, 10 and 20 lg/ml) of DHA for 2 days were detected with
speciﬁc antibodies. (C) Densitometric analysis of ZnT3 protein levels (normalised
with the b-actin protein levels) are shown in arbitrary units (AU). Molecular mass
protein markers (Mr) are indicated on the left of each gel. Data is representative of
three similar independent experiments. The data are shown as means (n = 3,
*P < 0.05).
Fig. 7. Immunoﬂuorescence analysis of ZnT3 protein localisation in M17 cells. Cells
were cultured either with 20 lg/ml DHA (A) or without DHA (B) for 2 days and ZnT3
proteins detected with ZnT3-speciﬁc primary antibody, followed by ﬂuorescent
secondary antibodies. Scale bars represent 20 lm.
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metabolism is well established, where the clinical symptoms of
zinc deﬁciency and PUFA deﬁciency are similar; disturbances in li-
pid metabolism occur in zinc deﬁcient patients and zinc-deﬁcient
pregnant rats have impaired transport of PUFA to the foetus [16].
We excluded the presence of a zinc–PUFA membrane transport
system. This was proven through data showing that DHA in the
culture medium did not affect 65Zn uptake over an 1 h period. Thus,
the membrane transport processes for zinc and DHA do not appear
to be linked. When M17 cells were grown in the presence of DHA
for 2 days prior to the addition 65Zn, however, a 65% reduction in
zinc accumulation was seen over a period of 1 h, providing direct
evidence that incorporated cellular DHA can inﬂuence zinc ﬂuxes.
Signiﬁcantly, this cell culture data is consistent with our previous
results that showed an increase in zinc levels in the synaptic vesi-
cles of rodents on DHA-deﬁcient diets [15].
Zinc homeostasis in the brain, including the uptake and efﬂux of
zinc from cells, is regulated by membrane-bound zinc transporters
belonging to members of the solute carrier 39 (SLC39) and the sol-
ute carrier 30 (SLC30), respectively [27,28]. The SLC39 transporters
are involved in the uptake of zinc into the cytoplasm while zinc
transporters of the SLC30 class, also known as ZnT, are involvedin compartmentalization of zinc from the cytoplasm into intracel-
lular vesicles or across the plasma membrane. In M17 cells, we de-
tected expression of numerous members of these two families
including Zip1, Zip2, Zip3, Zip4, ZnT1, ZnT2, ZnT3, ZnT4, ZnT5,
ZnT6 and ZnT7. The relative expression levels of these genes varied
considerably. A range of zinc transporters are expressed in the
mouse brain, including ZnT1, ZnT3, ZnT4, ZnT5, ZnT6 and ZnT7
[29]. Our results using M17 cells conﬁrm that human neuronal
cells express many members of the ZnT family as well as the Zip
family.
We focused our further studies on ZnT3 in relation to the effects
of DHA as this transporter is associated with brain zinc accumula-
tion as well as Alzheimer’s disease. ZnT3 co-localises with zinc
pools in the mouse brain [30] and Slc30a3 knockout mice show re-
duced zinc in hippocampal mossy ﬁbres [31]. ZnT3 is upregulated
in Alzheimer’s disease [29] and in APP/PS1 transgenic mice [32]
and the APP/DZnT3 double knockout mouse does not develop Alz-
heimer’s symptoms, indicating a critical role for ZnT3 in the path-
ogenesis of Alzheimer’s disease [33].
We previously showed that ZnT3 mRNA transcripts were in-
creased in the brains of rats on a DHA-deﬁcient diet relative to con-
trol animals [15]. This relationship was also seen here where
exposure of M17 cells to DHA concentrations of 10 and 40 lg/ml
decreased the expression of ZnT3 by 3.5 and more than 12-fold,
respectively, and was mirrored by a reduction in ZnT3 protein
Fig. 8. Schematic diagram of the mechanism of DHA in M17 cells. The key ﬁndings of this study are represented by the solid (black) arrows. Empty (white) arrows represent
possible beneﬁts of DHA in neuroprotection (NP) and lowering of zinc concentrations ([Zn]) in neuronal synaptic vesicles (SVs) and therefore contributing to lower incidence
of neurodegenerative diseases (ND), like Alzheimer’s disease (AD).
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in the cytoplasmic region of M17 cells, with a granular vesicular
distribution, DHA may function to decrease the ZnT3-mediated
transport of zinc from cytoplasm into intracellular vesicles. To
maintain zinc homeostasis and constant cytoplasmic zinc levels,
zinc uptake across the plasma membrane may therefore be
reduced.
Degenerative death of neurons in cortical brain regions is a key
feature of neurodegenerative disorders, including Alzheimer’s dis-
ease. Multiple evidence from studies in experimental models and
from brain tissue indicates that this neurodegeneration is a result
of neuronal cell apoptosis [34]. We found a direct link between
DHA treatment and inhibition of apoptosis in M17 cells where
more than a 66% reduction in active caspase-3 protein levels was
detected in cells treated with 20 lg/ml DHA, compared with the
untreated cells. Investigations into the mechanism of apoptotic cell
death indicate that the phosphatidylinositol 3-kinase/Akt signal-
ling is a critical pathway in this process and DHA acts in this path-
way. In cultured mouse neuroblastoma (Neuro 2A) cells, DHA
increased phosophatidyl serine levels resulting in translocation
and phosphorylation of Akt, dependent on phosphorylation of
Akt at Thr-308, that suppressed activation of caspase-3 [10]. This
Akt-dependent mechanism induced by DHA deﬁciency through
phosphatidyl serine is not known to involve zinc. Zinc, however,
phosphorylates Akt Thr-308 [35]. Zinc also directly activates Akt
by phosphorylation at Ser-473/Thr-308 leading to activation of
GSK-3beta and subsequent cell death, seen in cultured H19-7
embryonic hippocampal cells [36]. Thus, DHA may act to decrease
cellular zinc levels leading to increased Akt activity and reduced
apoptosis.
In summary, dietary DHA reduces the risk of cognitive decline
that is associated with neurodegenerative conditions including
Alzheimer’s disease. There is strong evidence that DHA acts
through inhibiting apoptosis. In the current study we have shown
that the DHA-induced decrease of apoptosis in M17 cells is accom-
panied by a decrease in cellular zinc uptake and reduction of ZnT3
mRNA and protein levels. We propose that zinc has a key role in
pathways that regulate brain cell survival and altered zinc homeo-
stasis may contribute to the development of neurodegenerative
disorders such as Alzheimer’s disease. To illustrate this, a model
of the DHA–zinc–apoptosis pathway is shown (Fig. 8, black ar-
rows). Here, ZnT3 imports zinc into synaptic vesicles [30,31] to
regulate zinc-dependent apoptosis. This model accounts for the po-
sitive effect of DHA in reducing neuronal cell death and neurode-
generative diseases such as Alzheimer’s disease (Fig. 8, white
arrows), whose incidence is reduced in populations with a high
omega-3 fatty acid diet.
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